A sensor for the detection of GPC-1 in a sample includes a substrate, a working electrode and counter electrode formed on a surface of the substrate, and an anti-GPC-1 antibody functionalized or chemically functionalized to a surface of an exposed portion of the working electrode.

Disclosed herein are compositions for assessing peptidoglycan biosynthesis in bacteria using modified dipeptides containing a bioorthogonal tag and applying novel post-labeling methods to label the bioorthogonal tag. The resultant, labeled peptidoglycan structures are amenable for identifying bacteria by microscopic visualization.

The invention provides anti-GPC3 antibodies and immunoconjugates and methods of using the same.

A method of diagnosing pancreatic cancer in a subject in need thereof is provided. The method comprising determining a level of at least syndecan 1 (SDC1) in a blood sample or a fraction thereof of the subject, wherein when the level of SDC1 is above a predetermined threshold, the subject is diagnosed with pancreatic cancer.

The present invention relates to methods for creating isotopically-labeled glycans or glycoconjugates for use in the analysis of glycans, and compositions produced from such methods. The present invention also relates to the use of isotopically labeled glycans or glycoconjugates as standards in glycan identification and/or quantification methods. In one embodiment, the method of the present invention can be used to accurately determine the levels of glycans in a sample based upon the addition of a known quantity of a standard comprising isotopically-labeled glycans to the sample prior to analysis. In one embodiment, the present invention relates to a composition for an analytical standard comprising one or more isotopically-labeled glycans or glycoconjugates.

The invention features compositions comprising an H3T3A mutant protein. Described herein are methods of inducing cell death in a rapidly dividing cell comprising contacting a rapidly dividing cell with an agent that reduces phosphorylation at threonine 3 of histone 3 (H3T3P), thereby inducing cell cycle arrest followed by cell death. In some cases, the rapidly dividing cell is a tumor cell, e.g., a cancer cell. The agent that reduces phosphorylation of H3T3P comprises an H3T3A mutant protein, e.g., a mutant transgenic protein. Described herein is a kit for arresting cell cycle comprising an agent that reduces phosphorylation H3T3P.

Provided are immunoconjugate probes useful for detecting hepatocellular carcinoma (HCC) lesions. The probes comprise a glypican-3 (GPC3)-specific monoclonal antibody or fragment thereof conjugated to a radionuclide such as .sup.89Zr, .sup.64Cu, and the like. The probes are useful for obtaining PET images with high tumor-to-liver ratios and targeting for diagnostic imaging of HCC lesions or cells in vitro and in vivo.

The present invention relates to the field of myocardial injury. More specifically, the present invention provides methods and compositions useful in the diagnosis, prognosis and/or assessment of myocardial injury. In a specific embodiment, a method comprises the steps of (a) diagnosing a subject as having myocardial injury based on the statistically significant over expression of one or more markers described herein compared to a baseline value, wherein the markers are measured in a biological sample obtained from the subject; and (b) treating the subject with one or more of an anti-thrombolysis agent, coronary bypass surgery or angioplasty.

The present invention relates to a biological method for assaying peptidoglycans (PGN) in a sample, particularly a sample of glucose polymers. The PGN assay includes: a) treating the glucose polymer sample by sonication, heating, and/or alkalizing; b) placing the treated sample or a dilution thereof in contact with a recombinant cell expressing an exogenous TLR2 (toll-like receptor 2) and a reporter gene directly dependent on the signaling pathway associated with the TLR2. The reporter gene codes for a colored or fluorescent protein or for a protein the activity of which is measurable with or without a substrate; c) measuring the reporter gene signal; and d) determining the amount of PUN in the sample using a standard curve of the correlation between the amount of PGN and the strength of the reporter gene signal.

The invention provides anti-GPC3 antibodies and immunoconjugates and methods of using the same.